TRISENOX Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Financing Rounds
  • 1

TRISENOX General Information

Description

Developer of arsenic trioxide injection. The company's product is indicated for induction of remission and consolidation in patients with acute promyelocytic leukemia (APL) who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • 41 Moores Road
  • Malvern, PA 19355
  • United States
+1 (610) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

TRISENOX Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore TRISENOX‘s full profile, request access.

Request a free trial

TRISENOX Executive Team (1)

Name Title Board Seat Contact Info
Danielle Leap Senior Product Manager
To view TRISENOX’s complete executive team members history, request access »